RxDoctor Payments Data

Dorothy Merritt, MD

Internal Medicine · la Marque, TXNPI 1881698579

Payments from drug & device makers

$2,038in general payments, 2019–2025

Across 95 payments — averaging $21.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$315
  • AstraZeneca$221
  • Boehringer Ingelheim$193
  • Amgen$179
  • GSK$152
  • Abbott$135
  • plus $843 from 17 others

What the payments were for

  • Food & beverage$2,02599%
  • Education$131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,038 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$3,370
Medicare patients
29
Services billed
37

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide36$41,032
OzempicSemaglutide20$30,629
JardianceEmpagliflozin26$29,544
EliquisApixaban21$10,630
ZtlidoLidocaine11$3,983
SynjardyEmpagliflozin/Metformin Hcl12$3,694
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen101$2,263
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$1,962
SynthroidLevothyroxine Sodium21$1,819
Albuterol Sulfate HfaAlbuterol Sulfate46$1,540
Levothyroxine Sodium102$1,158
Gabapentin58$1,070
Atorvastatin Calcium68$904
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine21$857
Quetiapine Fumarate22$853

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$56$41,03236 claims
Boehringer IngelheimJardiance, Synjardy$193$33,23838 claims
Novo NordiskOzempic$315$30,62920 claims
PfizerEliquis$96$10,63021 claims
AbbVieSynthroid$119$1,81921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in la Marque

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →